Neuromodulation Update: Mainstay Medical Raises €30m ($34m), Bluewind Medical Secures CE Mark
Executive Summary
Mainstay Medical raised an additional €30m ($34m) to fund the German launch and US PMA trial of its recently CE marked ReActiv8 implantable neurostimulation device for chronic low back pain. Bluewind Medical secured CE Mark for tibial neurostimulator for overactive bladder (OAB).